Abstract
Aberrant Wnt signaling within breast cancer is associated with poor prognosis, but regulation of this pathway in breast tissue remains poorly understood and the consequences of immediate or long-term dysregulation remain elusive. The exact contribution of the Wnt-regulating proteins APC and APC2 in the pathogenesis of human breast cancer are ill-defined, but our analysis of publically available array datasets indicates that tumors with concomitant low expression of both proteins occurs more frequently in the ‘triple negative’ phenotype, which is a subtype of breast cancer with particularly poor prognosis. We have used mouse transgenics to delete Apc and/or Apc2 from mouse mammary epithelium to elucidate the significance of these proteins in mammary homeostasis and delineate their influences on Wnt signaling and tumourigenesis. Loss of either protein alone failed to affect Wnt signaling levels or tissue homeostasis. Strikingly, concomitant loss led to local disruption of β-catenin status, disruption in epithelial integrity, cohesion and polarity, increased cell division and a distinctive form of ductal hyperplasia with ‘squamoid’ ghost cell nodules in young animals. Upon aging, the development of Wnt activated mammary carcinomas with squamous differentiation was accompanied by a significantly reduced survival. This novel Wnt driven mammary tumour model highlights the importance of functional redundancies existing between the Apc proteins both in normal homeostasis and in tumorigenesis.
Keywords: Apc2, Apc, Wnt signaling, Mammary gland, Tumourigenesis
Introduction
Breast cancer is one of the commonest malignancies in the Western world, accounting for a fifth of all deaths from cancer in women. Dysregulation of the Wnt signaling pathway is a frequent event in human cancers (1) and has been associated with both breast cancer initiation (2) and progression (3). The canonical Wnt pathway is multifaceted (reviewed in (4)), but central to it is β-catenin which acts as an intracellular signal transducer. Elevated expression, reduced membrane association and activation of β-catenin have been reported in human breast cancers and are associated with poor patient prognosis (3, 5–11). However, pathway mutations are rare (5, 6), and dysregulation most likely occurs due to subtle perturbation of the protein localization or through epigenetic means.
Both APC and APC2 can regulate β-catenin/Wnt signaling (12–14) and both are expressed in human mammary epithelium (15–17). Reduction of APC through loss of heterozygosity (15, 18), promoter hypermethylation (16, 19–22) and somatic mutation (23) has been reported in breast cancers. Reduced APC2 has also been implicated in breast cancer through loss of heterozygosity (24–26), allelic imbalance (17) and promoter hypermethylation (27). As both APC proteins can regulate Wnt signaling, both are expressed in mammary epithelium and loss of either has been linked with breast cancer, there is a possibility that functional redundancies exist in this tissue as they do in Drosophila development (28), but this has yet to be proven. Here, through the use of mouse transgenics, we show that concomitant loss of both mammary Apc proteins induces an aberrant hyperplastic phenotype in young mice that progresses with time into Wnt-driven tumours. These experiments underscore the importance of functional redundancies between the Apc proteins and present a useful Wnt driven mammary tumour model.
Results
The normal expression profile of both Apc and Apc2 in the mammary epithelium can be disrupted through the use of transgenic mouse models
Comprehensive loss of Apc2 within mammary epithelium occurs in mice harboring a constitutive homozygous Apc2 mutation (Apc2-/-) (29) (Fig. 1A), facilitating the exploration of the role of Apc2 in this tissue. Cre/loxP transgenesis utilizing Blg-Cre+ and Apcfl/fl alleles, (a transgenic combination used previously (30)), facilitates mammary epithelial specific loss of Apc whilst circumventing embryonic lethality associated with constitutive Apc loss (31). Cre-mediated recombination in virgin mammary glands occurs in a heterogeneous manner, determined using 10wk old glands from Blg-Cre+ mice crossed with the ROSA26 reporter strain (Supplemental Fig1). β-galactosidase fluorescent immunohistochemical (IHC) analysis corroborated a heterogeneous recombination pattern, occurring primarily in luminal cells (Fig. 1B). Note, the level of recombination is higher than 7% of cells as stated by Selbert et al (32), but in line with other studies using this Cre (30, 33). Apc IHC confirmed both the presence of Apc in Blg-CrenegativeApcfl/fl epithelium and the expected heterogeneous pattern of loss in Blg-Cre+Apcfl/fl glands (Fig. 1C). Together these results demonstrate that both Apc proteins are normally present in mammary epithelium and both can be disrupted through our selected transgenic models.
The combined disruption of both Apc and Apc2 leads to epithelial disruption, hyperplasia and lactation defects
Examination of 10wk old virgin mammary glands (n≥3) from four cohorts (Wild Type (termed Wt hereafter), Apc2-/-, Blg-Cre+Apcfl/fl and Blg-Cre+Apcfl/flApc2-/-) revealed that whilst either Apc2 or Apc alone were dispensable for mammary epithelial integrity, combined loss led to a range of epithelial defects (Fig. 2). Carmine alum stained glands revealed an epithelial thickening, reduced branching and disruption of epithelial structure, in 100% of Blg-Cre+Apcfl/flApc2-/- glands (Fig 2A- 2C). Furthermore, Blg-Cre+Apcfl/flApc2-/- glands displayed an unusual and distinctive form of ductal epithelial hyperplasia with prominent intraluminal, papillary, anucleate ‘ghost cell’ nodules, some of which underwent dislocation into the peri-ductal stroma (Supplemental Fig.2). Many of these ghost cell nodules had a ‘squamoid’ appearance, although other markers of squamous differentiation such as intercellular prickles (desmosomes) or keratin formation were not evident. Such ghost cell nodules have previously been seen following Apc inactivation (30), although their nature remains unclear. While this form of epithelial change is not recorded in human breast pathology, the phenomenon of ghost cells (or ‘shadow’ cells) is well recognized in certain other human tumours with ‘squamoid’ features, notably pilomatricomas, craniopharyngiomas and odontomes, where it may be accompanied by expression of so-called hard keratins (34) and, importantly in the context of our findings, aberrant β-catenin localization (34, 35).
Rates of cell turnover are normally relatively low in the mammary epithelium (36). However, mitotic figures were readily observable in Blg-Cre+Apcfl/flApc2-/- epithelium whilst seldom seen in other genotypes. The hyperplastic phenotype was confirmed by a statistically significant increase in Ki-67 labeled nuclei (Fig. 2D) in Blg-Cre+Apcfl/flApc2-/- mammary epithelium compared to all other genotypes. Interestingly, Apc2-/- displayed a significant decrease in proliferation compared to Wt mammary epithelium. Anti-cleaved caspase-3 IHC demonstrated that while cell death was seldom observed in Wt epithelium or in the single knock-out tissue, there was a statistical increase in labeled cells that extended into the ghost-cell nodules in Blg-Cre+Apcfl/flApc2-/- glands (Fig. 2D, 2E).
Females from each genotype were mated with stud males to induce pregnancy. Following birth all mothers and litters displayed normal suckling behavior regardless of genotype. However, whilst pups from Wt and Apc2-/- mothers were indistinguishable, in agreement with other studies, pups from Blg-Cre+Apcfl/fl failed to thrive (30). Additional loss of Apc2 accentuated this finding, whereby all pups from Blg-Cre+Apcfl/flApc2-/- mothers either died or had to be cross fostered by 5 days postpartum. Lack of observable milkspots in offspring in conjunction with normal suckling behavior suggested lactation defects. Histological examination of lactating mammary glands 5 days postpartum (Fig. 2D) revealed that while Wt and Apc2-/- glands both displayed fully differentiated milk producing alveoli and were indistinguishable, Blg-Cre+Apcfl/fl glands, as previously reported (30), displayed occasional intraluminal ghost-cell nodules and marginally perturbed alveolar formation, although milk production was still conspicuous. Contrary to this, differentiated alveoli were completely absent from Blg-Cre+Apcfl/flApc2-/- glands and tissue architecture was perturbed with disorganized ductular structures containing occasional densely eosinophilic luminal deposits. Together these results show that the Apc proteins play a functionally redundant role in the control of the differentiation of mammary epithelium into milk-producing alveoli essential for lactation.
Cellular positioning within the epithelia is perturbed following disruption of both Apc proteins
Given that virgin Apc2-/- and Blg-Cre+Apcfl/fl mammary glands appear indifferent from Wt, subsequent analyses were performed between virgin Blg-Cre+Apcfl/flApc2-/- and Blg-Cre+Apcfl/fl glands to compare the effects of additional Apc2 loss in the context of Apc deletion.
Cytokeratin 8 (luminal cell marker) and cytokeratin 5 (myoepithelial cell marker) staining (Fig. 2G) demonstrates well organized and highly polarized cells within the Blg-Cre+Apcfl/fl epithelium, consistent with that observed in Wt tissue (37). Contrary to this, Blg-Cre+Apcfl/flApc2-/- glands displayed a severe disruption to the normal organization, and a haphazard localization of luminal and basal (myoepithelial) cells suggesting a loss of positional identity. E-cadherin is the principal component of adherens junctions involved in cell-cell adhesion (reviewed in (38)) while Zo-1 is a component of tight junctions critical for maintaining barrier function (39). Together Zo-1 and E-cadherin have been shown to co-localize with β-catenin at the plasma membrane during the formation of the adherens and tight junctions, to co-immunoprecipitate (40), and to help establish and maintain epithelial polarity (41). Blg-Cre+Apcfl/fl epithelium maintains Zo-1 in the normal apical position and E-cadherin at a position consistent with cell-cell contacts (Fig. 2H). By contrast, Zo-1 is virtually absent from Blg-Cre+Apcfl/flApc2-/- epithelium, and there are occasional patches of cells displaying reduced levels of E-cadherin (Fig. 2H). The mechanisms through which Zo-1 is lost in the Blg-Cre+Apcfl/flApc2-/- epithelium requires further investigation, although it is possible that aberrant β-catenin localization and Wnt activation in the Blg-Cre+Apcfl/flApc2-/- mammary gland could contribute to the observed defects in positioning and adhesion. Activation of the Wnt signal pathway and nuclear translocation of β-catenin can suppress Zo-1 and E-cadherin activity, diminishing polarity (42, 43) whilst nuclear translocation of β-catenin and subsequent Wnt activation can promote reductions in cell adhesion (44, 45). However, it is clear that these results show functional redundancies between the Apc proteins in the maintenance of normal cellular positioning.
Combined disruption of both Apc and Apc2 leads to deregulated β-catenin status in a sub-set of epithelial cells
Both Apc proteins share the ability to mediate Wnt signaling through β-catenin degradation (1, 12–14, 46), while activating β-catenin mutations have been reported to induce mammary gland hyperplasia (47, 48). Analysis of β-catenin status (Fig. 3A) shows that β-catenin in Blg-Cre+Apcfl/fl epithelium, akin to Wt, displays a cytoplasmic and membrane bound expression pattern with the highest levels detected on the apical surface in a polarized manner. Conversely, in Blg-Cre+Apcfl/flApc2-/- glands the β-catenin staining pattern is disrupted in a heterogeneous manner, ranging from loss and mis-localization of β-catenin expression in some clusters of cells (Fig. 3 Aiv) to, areas displaying up-regulation and classical nuclear β-catenin staining in some cell clusters (Fig. 3A iii). Interestingly, nuclear localization of β-catenin was often found in epithelial cells at the periphery of the ghost-cell nodules (Supplemental Fig 2B), and aberrant β-catenin localization and activation leading to ‘squamoid’ transdifferentiation may well explain the presence of ghost cells in the Blg-Cre+Apcfl/flApc2-/- glands.
IHC analysis for Apc, β-catenin, cMyc and CD44 on serial sections of mammary glands from each genotype (Fig. 3B) confirmed that loss of Apc2 or Apc alone does not induce detectable changes in β-catenin localization or expression of the Wnt targets cMyc or CD44. It is pertinent to note that loss of Apc is not uniform even within the apparent areas aberrant morphology, with some cells maintaining expression of Apc (Fig 3.B). However, increased staining intensity of β-catenin, along with nuclear translocation in a subset of cells could be detected in Blg-Cre+Apcfl/flApc2-/- tissue. Furthermore, expression of cMyc was also detectable in a subset of cells within Blg-Cre+Apcfl/flApc2-/- tissue (Supplemental Fig 2C), suggestive of Wnt signaling activation, although CD44 changes remained undetectable. Thus, the pattern of changes is complex and does not lead to uniform activation of the Wnt pathway in all cells. The nature of Cre recombination in our model may account for the heterogeneous pattern of β-catenin staining, as it is possible that variations could arise as a consequence of Apc loss in different epithelial sub-populations. Alternately, the variations in β-catenin may represent different stages following the combined loss of the Apc proteins, but taken together, these results show that disruption of both Apc proteins results in aberrant β-catenin status within the mammary epithelium.
Disruption of Apc and Apc2 results in tumour formation
The long term consequences of loss of mammary epithelial Apc proteins were analyzed in cohorts of Wt, Apc2-/-, Blg-Cre+Apcfl/fl, Blg-Cre+Apcfl/fl Apc2+/- and Blg-Cre+Apcfl/flApc2-/- mice that were aged and sacrificed upon signs of ill health. Mice deficient for Apc2 or Apc alone displayed no differences in survival from Wt; however, the Blg-Cre+Apcfl/flApc2+/- and Blg-Cre+Apcfl/flApc2-/-cohorts displayed a significantly reduced survival (Fig. 4A). A reduction in survival in the Blg-Cre+Apcfl/flApc2-/- compared to Blg-Cre+Apcfl/flApc2+/- mice indicated an Apc2 gene dose dependent effect in the context of Apc loss. Furthermore, whilst Wt, Apc2-/- or Blg-Cre Apcfl/fl mice displayed no signs of mammary pathology, 46% of Blg-Cre+Apcfl/flApc2+/- mice (6 of 13) and 80% of Blg-Cre+Apcfl/flApc2-/- mice (8 of 10) presented with tumours in one or more mammary gland at the time of death (Fig. 4B). The epithelial integrity within 10wk old Blg-Cre+Apcfl/flApc2+/- glands is similar to Blg-Cre+Apcfl/flApc2-/- mice (Supplemental Fig 3), although the severity was somewhat reduced, confirming a gene dose dependent effect of Apc2 in the context of Apc mutation. It should be remembered that whilst APC2 mutation is infrequent, gene silencing through varying degrees of promoter hypermethylation is extremely common in human breast cancers (2). Levels of promoter methylation correlate with levels of reduced protein expression (2, 49). These observations imply that reduced expression levels of APC2 are sufficient for tumourigenesis in the appropriate context.
Histological analysis of mammary tissue harvested from aged mice at the time of death confirmed the presence of tumors solely within Blg-Cre+Apcfl/flApc2+/- and Blg-Cre+Apcfl/flApc2-/- mice (Fig. 4C) although, in agreement with previous studies, (30) occasional small clusters of ghost cells were present in Blg-Cre+Apcfl/fl glands. The breast tumours in both the Blg-Cre+Apcfl/flApc2+/- and Blg-Cre+Apcfl/flApc2-/- mice displayed squamous differentiation. They were both proliferative and invasive and were classified as well differentiated squamous carcinoma (Supplemental Fig 4). Metastasis to distant sites was not observed.
IHC analysis of the Wnt pathway in harvested tumours (Fig. 5) demonstrated a heterogeneous pattern of cMyc, CD44 and nuclear β-catenin staining, although areas of nuclear or up-regulated β-catenin also displayed increased cMyc expression in serial sections. Overexpression of cMyc, a global regulator of transcription (50) and a known Wnt target gene (51), has previously been reported to induce mammary carcinomas in mice (52) and found to be overexpressed in the majority of human breast tumours (53). Given Wnt pathway activation was only apparent in a subset of epithelial cells at an early time point, it is unclear whether these tumours arise due to Wnt activation in specific cell types, which one could speculate to be mammary stem cells or due to accumulation of other oncogenic mutations.
Taken together, therefore, our results show that the concomitant loss of both Apc proteins within mammary epithelium results in epithelial hyperplasia with squamoid ghost cell features at an early age, followed by the development of carcinomas showing squamous differentiation in aged mice, which is consistent with neoplastic progression.
APC and APC2 copy number in human breast cancer
To address the relevance of APC and APC2 in human breast cancer, we interrogated primary invasive ductal carcinomas from the publically available METABRIC (54) and TCGA BRCA (55) cohorts. From the 1,381 primary breast tumors in METABRIC, loss (copy number <2) of APC, located on 5q22.2, was observed in 96 (6.9%) and loss of APC2 on 19p13.3 in 118 (8.5%). In 54 (3.9%) samples, the genomic regions encompassing APC and APC2 were lost. In the 965 TCGA breast cancer samples, the genomic APC regions was lost in 108 samples (11.3%), APC2 in 91 (9.5%) and concurrent loss of APC and APC2 was seen in 35 (3.7%) of samples. Next we asked whether concurrent loss of APC and APC2 was breast cancer subtype specific and detected an enrichment of dual loss for triple-negative breast cancers (Fisher’s exact test two tailed p<0.0001 in both data sets) (Fig 6A). Additionally, loss of APC and APC2 results in increased expression of the Wnt signaling target genes cMYC and Sox9 (Fig 6B), lending further weight to the clinical relevance of the loss of both genes, especially for a difficult to treat subpopulation of human cancer patients.
To interrogate overall survival of breast cancer patients with concurrent APC and APC2 loss, we performed Kaplan Meier survival analyses in the METABRIC breast cancer cohort. The analysis demonstrates that patients with loss of either APC or APC2 display a reduced survival compared to patients with “no loss”, although survival of patients with loss of both APC and APC2 genes do not significantly differ to APC loss alone, suggesting that a synergistic affect between the two proteins does not exist with respect to survival (Fig. 6C).
Discussion
In this study we have assessed the functional redundancies between the Apc proteins in mammary epithelium and their roles in regulating Wnt transduction, tissue homeostasis and tumour formation. Although it is known that both Apc and Apc2 are able to regulate Wnt signaling (12–14), and that this pathway is frequently mis-regulated in many human cancers including breast cancer (1, 5–11), non-synonymous mutations in these genes within mammary tumours are rare (5, 6). The interplay between Apc and Apc2 in this setting has never before been explored.
Our model demonstrates that disruption of either Apc protein alone fails to induce any overt abnormal phenotype within the mammary gland, and reasserts the complexities that exist in regulating Wnt transduction, tissue homeostasis and tumour formation in this tissue. At the early time point analyzed, the mammary architecture was disrupted following the combined disruption of Apc and Apc2 despite the heterogeneous nature of the Blg-Cre driven gene recombination of APC. The mechanisms that give rise to this disruption have not been fully elucidated, although many Wnt independent roles for APC have been implicated in tumourigenesis (reviewed (56–58)). However, in addition to these potential Wnt independent mechanisms, nuclear β-catenin was observed in discrete areas of the gland and subtle activation of Wnt signaling could remain a contributing factor for the phenotype observed. Furthermore, upon aging, only mice possessing disruption of both Apc proteins displayed retarded survival and the appearance of tumours, which also displayed areas of nuclear β-catenin.
Thus, our findings highlight the notion that the relative levels of both proteins could be important in the pathogenesis of murine breast tumors and, by inference, potentially for the development of triple negative breast cancers in humans, a subtype with a particularly poor prognosis (59). Further, other contrasts and parallels between this model and human disease can provide important insights into the factors driving human mammary tumourigenesis through the loss of the APC proteins.
Materials and methods
Mice
All animal procedures were conducted in accordance with institutional animal care guidelines and UK Home Office regulations. Previously described Blg-Cre, Apcfl/fl alleles (30) and Apc2-/- mice (29) were interbred and maintained on a mixed C3H/C57BL6 genetic background. All animals were genotyped by PCR analysis of DNA extracted from ear mark clippings. For the aged cohorts the end point was reached if general health visually deteriorated or if mammary tumours arose and surpassed a set size (1.5cm diameter), blistered or restricted movement occurred.
Mammary gland Whole mount
Whole mammary glands were dissected, washed 3 times with 1XPBS (Sigma) following fixation in 4% PFA for 2 hours, then left in carmine alum solution (1g carmine (Invitrogen), 2.5g aluminum (Sigma) in 500ml distilled water) on a rocker overnight. Glands were then washed again 3 times with 1XPBS, dehydrated in increasing concentrations of ethanol and placed in xylene for 2 hours to clear fat. Glands were then mounted on slides using glycerol. Stained whole mounts were illuminated with a Leica CLS50X light source and visually analyzed under Olympus SZX12 low-magnification stereo microscope. Pictures were taken with Olympus C4040ZOOM 4.1 Megapixel digital camera. Branching events (Bifurcation) within the mammary gland was scored on n=3 glands for each genotype as previously described (60) and ducatal thickness of 30 ducts within each gland (n=3 for each genotype) was measured as described (61).
LacZ staining of whole mount mammary glands
Mammary whole mounts were fixed then stained using X-Gal staining solution: 1 mM MgCl2 (Sigma), 3 mM potassium ferricyanide (Sigma), 3 mM potassium ferrocyanide (Sigma) in 1X PBS. The solution was stored in a tinfoil wrapped bottle at −20°C and stock X-Gal solution (5% in DMF, Promega) 0.02% was added immediately prior to staining. The tissue was incubated with the staining solution overnight or until the sufficient level of staining was achieved at 37°C. Once stained, tissues were washed with 1X PBS and fixed with formalin to avoid further staining. Stained whole mounts were illuminated with Leica CLS50X light source and visually analyzed under Olympus SZX12 low-magnification stereo microscope. Pictures were taken with Olympus C4040ZOOM 4.1 Megapixel digital camera.
Tissue sections and immunohistochemistry (IHC)
To prepare sections, mammary glands and tumours were fixed in 4% paraformaldehyde for 2 hours or overnight respectively and then transferred to 70% ethanol. Tissues were dehydrated, embedded in paraffin and sectioned at 5µm using a Leica RM2135 microtome. Sections were later re-hydrated and either stained with hematoxylin and eosin then mounted or stained using IHC.
IHC Visualization using DAB
Antigen retrieval was achieved by heating slides in a microwave in 1X citrate buffer (LabVision) for 2 x 7 min (850 W). Slides were then left to cool in the solution for 30–60 min. Slides were then washed in dH2O for 5 mins followed by 2 x 5 min washes in washing buffer (1X TBS (Sigma) in dH2O with 0.1% (v/v) TWEEN-20 (Sigma)). Endogenous peroxidases were blocked by incubating tissue sections with hydrogen peroxide (Sigma) or a commercial peroxidase blocking solution (Envision+ Kit, DAKO). Slides were then blocked with a suitable serum for 1 hour at room temperature followed by an incubation period with primary antibody. Antibodies used were anti- Ki-67 (Vector Labs), Cleaved caspase-3 (Cell Signaling), β-catenin (BD Transduction Labs), cMyc (Santa Cruz) and CD44 (BD Pharmigen). Following primary incubation, slides were incubated with a suitable horseradish peroxidase conjugated secondary antibody (Envision+ Kit, DAKO), and either visualized using DAB (Envision+ Kit, DAKO) or the signal was amplified using ABC (Vectastain ABC kit, Vector labs) first then visualized with DAB. Sections were counterstained with Mayers Hemalum (R. A. Lamb) then mounted using DPX mounting medium (R. A. Lamb) ready for imaging on an Olympus BX41 light microscope. When required, the proportion of DAB positive epithelial cells was counted microscopically, n≥3 samples for each genotype, and at least 2000 cells counted per sample.
IHC Visualization using Fluorescence
For fluorescent immunohistochemistry, slides were processed as above up until the endogenous peroxidase activity block stage. This step was excluded. The serum block ((DAKO) or BSA (Sigma)) was applied for an incubation time of 30 min followed by an incubation period with primary antibody. Primary antibodies used were anti- APC2 (Zymed), β-glactosidase (Millipore), APC (Santa Cruz), CK5 (Abcam), CK8 (Abcam), Zo-1 (Zymed), E-cadherin (BD Transduction Labs) and β-catenin (BD Transduction Labs). Some slides were double labeled using two primary antibodies and two corresponding fluorescently labeled secondary antibodies. Care was taken when selecting antibodies to avoid cross-reactivity. Exposure to daylight of the secondary antibody solution and stained sections was kept to a minimum to avoid photo-bleaching. The slides were incubated with secondary antibodies (suitable Alexafluor 488 and/or Alexafluor 594 (Invitrogen)) for 1-2 hours. Following the final wash with wash buffer after incubation with the secondary antibodies, slides were washed in 1X PBS (Invitrogen) and mounted without dehydration using Vectashield hardset mounting medium with DAPI (DAPI labels nuclear material blue) (Vector Labs). Slides were kept in the dark at 4°C and imaged within 2 weeks. Images were taken using an Olympus BX61 with correct filters and lamp for detecting fluorescent probes.
Bioinformatics analysis
The METABRIC (54) data was acquired from the European Genome-Phenome Archive (EGAD00010000164) and normalized as described previously (62). The TCGA (55) clinical and RNASeqV2 data was obtained from the TCGA Data Portal. For the METABRIC data, triple-negative status was defined by IHC of ER and HER2. For TCGA data the IHC status of ER, HER2 and PR was used. Raw Affymetrix SNP 6.0 microarray data was processed using PennCNV-Affy (63). Copy number data was obtained using the allele-specific copy number analysis of tumors (ASCAT) algorithm. Tumours with loss of APC and APC2 were identified and their pathophysiological classification noted.
Supplementary Material
Acknowledgements
This project was funded by Biotechnology and Biomedical Sciences Research Council and Cancer Research UK (ARC Programme grant C1295/ A15937). GTW is supported by the Wales Gene Park. Jelmar Quist is funded by a PhD studentship from the NIHR Biomedical Research Centre at Guy’s and St Thomas. Anita Grigoriadis is supported by Breast Cancer NOW (former Breakthrough Breast Cancer Research). We thank Luke Bradshaw, Oro Asby, Bridget Allen and Elaine Taylor for assistance with mouse husbandry. We would also like to thank Mark Bishop and Matthew Zverev for technical support and genotyping and Derek Scarborough and Marc Isaacs for their assistance in histology.
Abbreviations List
- APC
Adenomatous polyposis coli
- H&E
Hematoxylin and Eosin
- IHC
Immunohistochemistry
- Wt
Wild Type
Footnotes
Conflict of Interest:
All authors confirm that there are no conflicts of interest to disclose
References
- 1.Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006 Nov;127(3):469–80. doi: 10.1016/j.cell.2006.10.018. [DOI] [PubMed] [Google Scholar]
- 2.Mohinta S, Wu H, Chaurasia P, Watabe K. Wnt pathway and breast cancer. Front Biosci. 2007;12:4020–33. doi: 10.2741/2368. [DOI] [PubMed] [Google Scholar]
- 3.Khalil S, Tan GA, Giri DD, Zhou XK, Howe LR. Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS One. 2012;7(3):e33421. doi: 10.1371/journal.pone.0033421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012 Jun;149(6):1192–205. doi: 10.1016/j.cell.2012.05.012. [DOI] [PubMed] [Google Scholar]
- 5.Jönsson M, Borg A, Nilbert M, Andersson T. Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer. 2000 Jan;36(2):242–8. doi: 10.1016/s0959-8049(99)00276-2. [DOI] [PubMed] [Google Scholar]
- 6.Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, et al. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011 Feb;24(2):209–31. doi: 10.1038/modpathol.2010.205. [DOI] [PubMed] [Google Scholar]
- 7.Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000 Apr;97(8):4262–6. doi: 10.1073/pnas.060025397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006 May;66(10):5487–94. doi: 10.1158/0008-5472.CAN-06-0100. [DOI] [PubMed] [Google Scholar]
- 9.López-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, et al. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):301–9. doi: 10.1158/1055-9965.EPI-09-0741. [DOI] [PubMed] [Google Scholar]
- 10.Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA. Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol. 2009 Mar;24(3):385–98. doi: 10.14670/HH-24.385. [DOI] [PubMed] [Google Scholar]
- 11.Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010 Jun;176(6):2911–20. doi: 10.2353/ajpath.2010.091125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.van Es JH, Kirkpatrick C, van de Wetering M, Molenaar M, Miles A, Kuipers J, et al. Identification of APC2, a homologue of the adenomatous polyposis coli tumour suppressor. Curr Biol. 1999 Jan;9(2):105–8. doi: 10.1016/s0960-9822(99)80024-4. [DOI] [PubMed] [Google Scholar]
- 13.Roberts DM, Pronobis MI, Poulton JS, Kane EG, Peifer M. Regulation of Wnt signaling by the tumor suppressor adenomatous polyposis coli does not require the ability to enter the nucleus or a particular cytoplasmic localization. Mol Biol Cell. 2012 Jun;23(11):2041–56. doi: 10.1091/mbc.E11-11-0965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Schneikert J, Vijaya Chandra SH, Ruppert JG, Ray S, Wenzel EM, Behrens J. Functional comparison of human adenomatous polyposis coli (APC) and APC-like in targeting beta-catenin for degradation. PLoS One. 2013;8(7):e68072. doi: 10.1371/journal.pone.0068072. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kashiwaba M, Tamura G, Ishida M. Aberrations of the APC gene in primary breast carcinoma. J Cancer Res Clin Oncol. 1994;120(12):727–31. doi: 10.1007/BF01194271. [DOI] [PubMed] [Google Scholar]
- 16.Schlosshauer PW, Pirog EC, Levine RL, Ellenson LH. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol. 2000 Oct;13(10):1066–71. doi: 10.1038/modpathol.3880196. [DOI] [PubMed] [Google Scholar]
- 17.Jarrett CR, Blancato J, Cao T, Bressette DS, Cepeda M, Young PE, et al. Human APC2 localization and allelic imbalance. Cancer Res. 2001 Nov;61(21):7978–84. [PubMed] [Google Scholar]
- 18.Thompson AM, Morris RG, Wallace M, Wyllie AH, Steel CM, Carter DC. Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. Br J Cancer. 1993 Jul;68(1):64–8. doi: 10.1038/bjc.1993.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M, et al. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer. 2001 Jul;85(1):69–73. doi: 10.1054/bjoc.2001.1853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ho KY, Kalle WH, Lo TH, Lam WY, Tang CM. Reduced expression of APC and DCC gene protein in breast cancer. Histopathology. 1999 Sep;35(3):249–56. doi: 10.1046/j.1365-2559.1999.00725.x. [DOI] [PubMed] [Google Scholar]
- 21.Sarrió D, Moreno-Bueno G, Hardisson D, Sánchez-Estévez C, Guo M, Herman JG, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer. 2003 Aug;106(2):208–15. doi: 10.1002/ijc.11197. [DOI] [PubMed] [Google Scholar]
- 22.Van der Auwera I, Van Laere SJ, Van den Bosch SM, Van den Eynden GG, Trinh BX, van Dam PA, et al. Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer. 2008 Nov;99(10):1735–42. doi: 10.1038/sj.bjc.6604705. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Furuuchi K, Tada M, Yamada H, Kataoka A, Furuuchi N, Hamada J, et al. Somatic mutations of the APC gene in primary breast cancers. Am J Pathol. 2000 Jun;156(6):1997–2005. doi: 10.1016/s0002-9440(10)65072-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Sobottka SB, Haase M, Fitze G, Hahn M, Schackert HK, Schackert G. Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J Neurooncol. 2000 Sep;49(3):187–95. doi: 10.1023/a:1006442024874. [DOI] [PubMed] [Google Scholar]
- 25.Yang TL, Su YR, Huang CS, Yu JC, Lo YL, Wu PE, et al. High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity. Genes Chromosomes Cancer. 2004 Nov;41(3):250–6. doi: 10.1002/gcc.20080. [DOI] [PubMed] [Google Scholar]
- 26.Wang ZJ, Churchman M, Campbell IG, Xu WH, Yan ZY, McCluggage WG, et al. Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer. 1999 Apr;80(1-2):70–2. doi: 10.1038/sj.bjc.6690323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008 May;5(5):e114. doi: 10.1371/journal.pmed.0050114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Ahmed Y, Nouri A, Wieschaus E. Drosophila Apc1 and Apc2 regulate Wingless transduction throughout development. Development. 2002 Apr;129(7):1751–62. doi: 10.1242/dev.129.7.1751. [DOI] [PubMed] [Google Scholar]
- 29.van der Meer M, Baumans V, Hofhuis FM, Olivier B, van Zutphen BF. Consequences of gene targeting procedures for behavioural responses and morphological development of newborn mice. Transgenic Res. 2001 Oct;10(5):399–408. doi: 10.1023/a:1012244404020. [DOI] [PubMed] [Google Scholar]
- 30.Gallagher RC, Hay T, Meniel V, Naughton C, Anderson TJ, Shibata H, et al. Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency. Oncogene. 2002 Sep;21(42):6446–57. doi: 10.1038/sj.onc.1205892. [DOI] [PubMed] [Google Scholar]
- 31.Moser AR, Shoemaker AR, Connelly CS, Clipson L, Gould KA, Luongo C, et al. Homozygosity for the Min allele of Apc results in disruption of mouse development prior to gastrulation. Dev Dyn. 1995 Aug;203(4):422–33. doi: 10.1002/aja.1002030405. [DOI] [PubMed] [Google Scholar]
- 32.Selbert S, Bentley DJ, Melton DW, Rannie D, Lourenço P, Watson CJ, et al. Efficient BLG-Cre mediated gene deletion in the mammary gland. Transgenic Res. 1998 Sep;7(5):387–96. doi: 10.1023/a:1008848304391. [DOI] [PubMed] [Google Scholar]
- 33.Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev. 1999 Oct;13(19):2604–16. doi: 10.1101/gad.13.19.2604. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Tanaka A, Okamoto M, Yoshizawa D, Ito S, Alva PG, Ide F, et al. Presence of ghost cells and the Wnt signaling pathway in odontomas. J Oral Pathol Med. 2007 Aug;36(7):400–4. doi: 10.1111/j.1600-0714.2007.00550.x. [DOI] [PubMed] [Google Scholar]
- 35.Hassanein AM, Glanz SM, Kessler HP, Eskin TA, Liu C. beta-Catenin is expressed aberrantly in tumors expressing shadow cells. Pilomatricoma, craniopharyngioma, and calcifying odontogenic cyst. Am J Clin Pathol. 2003 Nov;120(5):732–6. doi: 10.1309/EALE-G7LD-6W71-67PX. [DOI] [PubMed] [Google Scholar]
- 36.Neese RA, Misell LM, Turner S, Chu A, Kim J, Cesar D, et al. Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci U S A. 2002 Nov;99(24):15345–50. doi: 10.1073/pnas.232551499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76. doi: 10.1186/gb-2007-8-5-r76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996 Feb;84(3):345–57. doi: 10.1016/s0092-8674(00)81279-9. [DOI] [PubMed] [Google Scholar]
- 39.Umeda K, Ikenouchi J, Katahira-Tayama S, Furuse K, Sasaki H, Nakayama M, et al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell. 2006 Aug;126(4):741–54. doi: 10.1016/j.cell.2006.06.043. [DOI] [PubMed] [Google Scholar]
- 40.Rajasekaran AK, Hojo M, Huima T, Rodriguez-Boulan E. Catenins and zonula occludens-1 form a complex during early stages in the assembly of tight junctions. J Cell Biol. 1996 Feb;132(3):451–63. doi: 10.1083/jcb.132.3.451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Ando-Akatsuka Y, Yonemura S, Itoh M, Furuse M, Tsukita S. Differential behavior of E-cadherin and occludin in their colocalization with ZO-1 during the establishment of epithelial cell polarity. J Cell Physiol. 1999 May;179(2):115–25. doi: 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
- 42.Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A. 1999 Feb;96(4):1603–8. doi: 10.1073/pnas.96.4.1603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Reichert M, Müller T, Hunziker W. The PDZ domains of zonula occludens-1 induce an epithelial to mesenchymal transition of Madin-Darby canine kidney I cells. Evidence for a role of beta-catenin/Tcf/Lef signaling. J Biol Chem. 2000 Mar;275(13):9492–500. doi: 10.1074/jbc.275.13.9492. [DOI] [PubMed] [Google Scholar]
- 44.Yook JI, Li XY, Ota I, Fearon ER, Weiss SJ. Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem. 2005 Mar;280(12):11740–8. doi: 10.1074/jbc.M413878200. [DOI] [PubMed] [Google Scholar]
- 45.DiMeo TA, Anderson K, Phadke P, Fan C, Feng C, Perou CM, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009 Jul;69(13):5364–73. doi: 10.1158/0008-5472.CAN-08-4135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 2004 Jun;18(12):1385–90. doi: 10.1101/gad.287404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Michaelson JS, Leder P. beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene. 2001 Aug;20(37):5093–9. doi: 10.1038/sj.onc.1204586. [DOI] [PubMed] [Google Scholar]
- 48.Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P. Delta N89 beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol. 2001 Apr;153(3):555–68. doi: 10.1083/jcb.153.3.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet. 2008 Jun;9(6):465–76. doi: 10.1038/nrg2341. [DOI] [PubMed] [Google Scholar]
- 50.Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006 Aug;16(4):253–64. doi: 10.1016/j.semcancer.2006.07.014. [DOI] [PubMed] [Google Scholar]
- 51.He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998 Sep;281(5382):1509–12. doi: 10.1126/science.281.5382.1509. [DOI] [PubMed] [Google Scholar]
- 52.Hutchinson JN, Muller WJ. Transgenic mouse models of human breast cancer. Oncogene. 2000 Dec;19(53):6130–7. doi: 10.1038/sj.onc.1203970. [DOI] [PubMed] [Google Scholar]
- 53.Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer. 2000 Sep;7(3):143–64. doi: 10.1677/erc.0.0070143. [DOI] [PubMed] [Google Scholar]
- 54.Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012 Jun 21;486(7403):346–52. doi: 10.1038/nature10983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4;490(7418):61–70. doi: 10.1038/nature11412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. Journal of cell science. 2007 Oct 1;120(Pt 19):3327–35. doi: 10.1242/jcs.03485. [DOI] [PubMed] [Google Scholar]
- 57.Lesko AC, Goss KH, Prosperi JR. Exploiting APC Function as a Novel Cancer Therapy. Curr Drug Targets. 2014 Jan;15(1):90–102. doi: 10.2174/1389450114666131108155418. [DOI] [PubMed] [Google Scholar]
- 58.Nelson S, Nathke IS. Interactions and functions of the adenomatous polyposis coli (APC) protein at a glance. Journal of cell science. 2013 Feb 15;126(4):873–7. doi: 10.1242/jcs.100479. [DOI] [PubMed] [Google Scholar]
- 59.Irshad S, Ellis P, Tutt A. Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Current opinion in oncology. 2011 Nov;23(6):566–77. doi: 10.1097/CCO.0b013e32834bf8ae. [DOI] [PubMed] [Google Scholar]
- 60.Bray K, Gillette M, Young J, Loughran E, Hwang M, Sears JC, et al. Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration. Breast Cancer Res. 2013;15(5):R91. doi: 10.1186/bcr3487. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, et al. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol. 2006 Nov;169(5):1784–801. doi: 10.2353/ajpath.2006.060590. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, et al. Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. Cancer discovery. 2015 May;5(5):488–505. doi: 10.1158/2159-8290.CD-14-1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome research. 2007 Nov;17(11):1665–74. doi: 10.1101/gr.6861907. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.